The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of cemiplimab, a human monoclonal antibody to programmed death (PD)-1, in Japanese patients (pts) with advanced malignancies: Results from the dose exploration.
 
Shigehisa Kitano
Honoraria - AstraZeneca; AYUMI; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Meiji Seika Kaisha; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sumitomo Group; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Novartis; Ono Pharmaceutical
Research Funding - Astellas Pharma; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Gilead Sciences; Ono Pharmaceutical; REGENERON; Takara Bio
 
Toshio Shimizu
Honoraria - Millennium
Consulting or Advisory Role - Millennium
Speakers' Bureau - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Millennium
 
Takafumi Koyama
No Relationships to Disclose
 
Takahiro Ebata
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Otsuka (Inst)
 
Shunsuke Kondo
No Relationships to Disclose
 
Akihiko Shimomura
No Relationships to Disclose
 
Yutaka Fujiwara
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Eisai; OncoTherapy Science; Otsuka; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Janssen (I); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Anne Josee Paccaly
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Clifford Baum
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Siyu Li
Employment - Novartis; Regeneron
Stock and Other Ownership Interests - Regeneron
 
Petra Rietschel
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Honoraria - Regeneron
 
Tasha Nicholle Sims
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
Travel, Accommodations, Expenses - Regeneron